Botanix Pharmaceuticals LimitedASX: BOT

Botanix Quarterly Activities Report and Appendix 4C Q1 FY27

· Issued by Botanix Pharmaceuticals Limited via ASX

Filed with ASX · · 11 pages · English

Summary by 6ix AI

The report highlights a growth in total prescriptions shipped and a decrease in operating cash outflows, indicating improved financial management. Additionally, the company has initiated cost actions to extend its cash runway and enhance strategic opportunities. The report also mentions a new US patent for its drug substance and a supply agreement aimed at reducing costs.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/botanix-quarterly-activities-report-and-appendix-4c-q1-fy27

Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call

Release

27 October 2026 Botanix Pharmaceuticals Quarterly Activity Report and 4C Quarterly Cash Flow Report Q1 FY27 PHOENIX, USA – 27 October 2026: Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), is pleased to release its...

Botanix Pharmaceuticals Limited on 6ix

In the deck

Story so far

Earlier from Botanix Pharmaceuticals

Later from Botanix Pharmaceuticals

All Botanix Pharmaceuticals news releases